Fierce New Product Planning 2024

• We will emphasize the necessity of early positioning in the drug development process and its cross-functional nature.
• Discuss the common mistake of late positioning and the benefits of integrating positioning strategies before designing phase three trials.
• Hear real-world examples to illustrate the impact of early positioning on product success.
• Understand how early positioning is a critical precursor to a successful product launch, avoiding rigid phase three protocols that limit strategic flexibility.
  

As Medicare’s Maximum Fair Prices (MFPs) for the first ten selected drugs have finally been released, IRA is again at the forefront of forecasting, market access, patient services, and BD/portfolio strategy teams' minds as they grapple with the future prospects of their lead development programs. Strategically setting price and cost of access as assets approach launch is no longer enough to realize the full value of a program – teams must now consider how to maximize value even as they select candidates for clinical development. Join Triangle Insights Group for an interactive presentation where our Pricing and Market Access and New Product Planning leadership outlines potential approaches to maximize near-term ROI and long-term revenue potential in the age of IRA drug pricing provisions, including:

• A general overview of key updates to IRA drug pricing provisions from the most recent guidance
• The evolution of strategies for candidate selection and development in the context of the IRA drug pricing provisions
• An interactive product profile selection and design process based on characteristics favorable to the IRA landscape

Delve into the strategic importance of Target Product Profiles (TPPs) in pharmaceutical development with a panel of industry experts. This discussion will explore advanced strategies, key considerations, and real-world applications of TPPs to optimize drug development outcomes.

• Discuss the role of TPPs in facilitating smoother regulatory reviews and negotiations, and preparing for market access challenges.
• Strategies for updating TPPs in response to new clinical data, regulatory feedback, and changes in the competitive landscape to keep the development process agile.
• Real-World Applications: Analyze case studies that highlight both successful implementations and common pitfalls of TPPs in drug development, offering practical insights and actionable strategies.

Join us for an exciting and interactive session where we reveal the top three value-added oncology programs, identified through our research study with oncologists and payers. These insights are essential for pharmaceutical companies looking to enhance their product offerings.

What to Expect:

• Industry Perspectives: Ray Gomez, who has spearheaded transformations at leading pharmaceutical companies like Bristol Myers Squibb and Novartis, will provide expert commentary and industry insights.
• Get Past 'Planning' – See Tangible Examples: Sherif Salti, Founder and Global Managing Partner of SALTI, will showcase the top three customer engagement journeys that stand out based on our research.
• Interactive Experience: This session isn’t just a presentation—you’ll have the chance to ask questions, share ideas, and see real examples in action.
  
  

Come ready to engage, learn, and walk away with clear, actionable steps to elevate your new product planning strategies in oncology.

Michelle Robertson, EVP, CFO and Treasurer of Geron, will present a case study on how to prepare a company for the transition from a clinical development to a commercial organization based on her experiences launching a first-of-its-kind medicine.

In June 2024, Geron received FDA approval for RYTELO™ (imetelstat), the first-ever telomerase inhibitor, for the treatment of certain adults with lower-risk MDS with transfusion-dependent anemia, following a multi-decade scientific and drug development journey to bring the potential of telomerase inhibition to patients. Key takeaways will include how and where to invest your resources; mitigating risks as a company doubles in size; and making strategic investments to set your company up for success.

• Best practices to maximize capital use and minimize waste across development phases and launch.
• Flexible and robust budgeting techniques that adapt to unexpected changes and regulatory shifts in development.
• Long-term financial strategies that align with business goals and maintain investor confidence. 

• Better prepare your organization to effectively evaluate the commercial potential of early-stage assets and have greater confidence in the key strategic decisions you need to make for your early pipeline
• Reimagine the traditional prioritization of activities when exploring a new asset’s viability globally
• Explore the key stage-gates to a successful product life cycle, including what to do, when to do it, and how much investment is “worth it”
• Rethink how more effective cross-functional collaboration can advance your new product planning team